FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313909535> ?p ?o ?g. }

• W4313909535 endingPage "856" @default.
• W4313909535 startingPage "843" @default.
• W4313909535 abstract "This study was undertaken to estimate the cost-effectiveness of add-on cenobamate in the UK when used to treat drug-resistant focal seizures in adults who are not adequately controlled with at least two prior antiseizure medications, including at least one used adjunctively.We estimated the cost per quality-adjusted life-year (QALY) for cenobamate compared to brivaracetam, eslicarbazepine, lacosamide, and perampanel in the UK National Health Service over a lifetime time horizon. We used a Markov cohort structure to determine response to treatment, using pooled data from three long-term studies of cenobamate. A network meta-analysis informed the likelihood of response to therapy with brivaracetam, eslicarbazepine, lacosamide, and perampanel relative to cenobamate. Once individuals discontinued treatment, they transitioned to subsequent treatment health states, including other antiseizure medicines, surgery, and vagus nerve stimulation. Costs included treatment, administration, routine monitoring, event management, and adverse events. Published evidence and expert opinion informed the likelihood of response to subsequent treatments, associated adverse events, and costs. Utility data were based on Short-Form six-dimension form utility. Discounting was applied at 3.5% per annum as per National Institute for Health and Care Excellence guidance. Uncertainty was explored through deterministic and probabilistic sensitivity analyses.In the base case, cenobamate led to cost savings of £51 967 (compared to brivaracetam), £21 080 (compared to eslicarbazepine), £33 619 (compared to lacosamide), and £28 296 (compared to perampanel) and increased QALYs of 1.047 (compared to brivaracetam), 0.598 (compared to eslicarbazepine), 0.776 (compared to lacosamide), and 0.703 (compared to perampanel) per individual over a lifetime time horizon. Cenobamate also dominated the four drugs across most sensitivity analyses. Differences were due to reduced seizure frequency with cenobamate relative to comparators.Cenobamate improved QALYs and was less costly than brivaracetam, eslicarbazepine, lacosamide, and perampanel. Therefore, cenobamate may be considered as a cost-effective adjunctive antiseizure medication for people with drug-resistant focal seizures." @default.
• W4313909535 created "2023-01-10" @default.
• W4313909535 creator A5016811008 @default.
• W4313909535 creator A5022408915 @default.
• W4313909535 creator A5035080758 @default.
• W4313909535 creator A5035657409 @default.
• W4313909535 creator A5056130670 @default.
• W4313909535 creator A5067330336 @default.
• W4313909535 creator A5075133953 @default.
• W4313909535 creator A5083329897 @default.
• W4313909535 date "2023-02-14" @default.
• W4313909535 modified "2023-10-10" @default.
• W4313909535 title "Cost‐effectiveness of cenobamate for focal seizures in people with drug‐resistant epilepsy" @default.
• W4313909535 cites W1498758291 @default.
• W4313909535 cites W1572262481 @default.
• W4313909535 cites W1703571579 @default.
• W4313909535 cites W1997577127 @default.
• W4313909535 cites W2012369961 @default.
• W4313909535 cites W2014747949 @default.
• W4313909535 cites W2016326495 @default.
• W4313909535 cites W2016716250 @default.
• W4313909535 cites W2058596886 @default.
• W4313909535 cites W2064152721 @default.
• W4313909535 cites W2121371311 @default.
• W4313909535 cites W2135808877 @default.
• W4313909535 cites W2143243043 @default.
• W4313909535 cites W2159017878 @default.
• W4313909535 cites W2163886527 @default.
• W4313909535 cites W2405298355 @default.
• W4313909535 cites W2472978162 @default.
• W4313909535 cites W2624406735 @default.
• W4313909535 cites W2625285695 @default.
• W4313909535 cites W2750954924 @default.
• W4313909535 cites W2777270043 @default.
• W4313909535 cites W2796760753 @default.
• W4313909535 cites W2801336581 @default.
• W4313909535 cites W2905474733 @default.
• W4313909535 cites W2959900350 @default.
• W4313909535 cites W2988342087 @default.
• W4313909535 cites W3013153485 @default.
• W4313909535 cites W3025465714 @default.
• W4313909535 cites W3025691036 @default.
• W4313909535 cites W3040749770 @default.
• W4313909535 cites W3188718543 @default.
• W4313909535 cites W4200133286 @default.
• W4313909535 doi "https://doi.org/10.1111/epi.17506" @default.
• W4313909535 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36625423" @default.
• W4313909535 hasPublicationYear "2023" @default.
• W4313909535 type Work @default.
• W4313909535 citedByCount "4" @default.
• W4313909535 countsByYear W43139095352023 @default.
• W4313909535 crossrefType "journal-article" @default.
• W4313909535 hasAuthorship W4313909535A5016811008 @default.
• W4313909535 hasAuthorship W4313909535A5022408915 @default.
• W4313909535 hasAuthorship W4313909535A5035080758 @default.
• W4313909535 hasAuthorship W4313909535A5035657409 @default.
• W4313909535 hasAuthorship W4313909535A5056130670 @default.
• W4313909535 hasAuthorship W4313909535A5067330336 @default.
• W4313909535 hasAuthorship W4313909535A5075133953 @default.
• W4313909535 hasAuthorship W4313909535A5083329897 @default.
• W4313909535 hasBestOaLocation W43139095351 @default.
• W4313909535 hasConcept C118552586 @default.
• W4313909535 hasConcept C126322002 @default.
• W4313909535 hasConcept C177713679 @default.
• W4313909535 hasConcept C197934379 @default.
• W4313909535 hasConcept C24998067 @default.
• W4313909535 hasConcept C2778139780 @default.
• W4313909535 hasConcept C2778186239 @default.
• W4313909535 hasConcept C2780087125 @default.
• W4313909535 hasConcept C2780836401 @default.
• W4313909535 hasConcept C2781404750 @default.
• W4313909535 hasConcept C71924100 @default.
• W4313909535 hasConcept C98274493 @default.
• W4313909535 hasConceptScore W4313909535C118552586 @default.
• W4313909535 hasConceptScore W4313909535C126322002 @default.
• W4313909535 hasConceptScore W4313909535C177713679 @default.
• W4313909535 hasConceptScore W4313909535C197934379 @default.
• W4313909535 hasConceptScore W4313909535C24998067 @default.
• W4313909535 hasConceptScore W4313909535C2778139780 @default.
• W4313909535 hasConceptScore W4313909535C2778186239 @default.
• W4313909535 hasConceptScore W4313909535C2780087125 @default.
• W4313909535 hasConceptScore W4313909535C2780836401 @default.
• W4313909535 hasConceptScore W4313909535C2781404750 @default.
• W4313909535 hasConceptScore W4313909535C71924100 @default.
• W4313909535 hasConceptScore W4313909535C98274493 @default.
• W4313909535 hasFunder F4320323946 @default.
• W4313909535 hasIssue "4" @default.
• W4313909535 hasLocation W43139095351 @default.
• W4313909535 hasLocation W43139095352 @default.
• W4313909535 hasLocation W43139095353 @default.
• W4313909535 hasLocation W43139095354 @default.
• W4313909535 hasOpenAccess W4313909535 @default.
• W4313909535 hasPrimaryLocation W43139095351 @default.
• W4313909535 hasRelatedWork W2055553936 @default.
• W4313909535 hasRelatedWork W3128060880 @default.
• W4313909535 hasRelatedWork W3164186905 @default.
• W4313909535 hasRelatedWork W3175656374 @default.
• W4313909535 hasRelatedWork W4243503705 @default.

• next